Reverse Stock Splits and Dilution Risk: The Case of CalciMedica (CALC)

Key Risk: Reverse Stock Splits Often Signal Desperation, Not Strategy

CalciMedica, Inc. (CALC), a small-cap biotech company with a $12.9M market cap, has not traded above $0.01 in recent months (listed as “$None” per provided data). While a reverse stock split (RSS) could technically elevate its share price to meet exchange listing requirements, the move would likely signal severe financial distress and heightened dilution risk for existing shareholders. Historical data shows that small-cap biotechs announcing RSSs often follow through with equity issuances that dilute existing stakeholders by 20%+ within 12 months.

### Liquidity and Market Sentiment Concerns

A reverse stock split does not inherently dilute shareholders, but it is almost always a precursor to dilutive capital raises. For CALC, an RSS would likely be motivated by its critical need to avoid delisting from the Nasdaq, which requires a minimum $1.00 share price or $500M market cap. At $12.9M, CALC is orders of magnitude below this threshold, leaving an RSS as its most plausible lifeline.

However, such moves come with significant trade-offs:

1. Liquidity Erosion: Smaller market caps inherently struggle with thin order books. Post-RSS, trading volume often plummets further, widening bid-ask spreads and making it harder for shareholders to exit.

2. Investor Psychology: An RSS often stigmatizes a stock as a “penny stock,” deterring institutional interest and accelerating the outflow of retail capital. This dynamic has been observed in peers like HNB (HNBG), which saw its average daily volume drop 7